Non categorizzato

Andrea Toborelli (Business Development and Licensing Manager), Shawn Valenti (Business Development Manager) and Beatrice Pisano (Senior Business Development Communication Specialist) at IBSA were interview by Chimica Oggi – Chemistry Today.

Osteoarthritis, the most common cause of musculoskeletal disability. Let’s find out more with the IBSA NAHYCO® HYBRID TECHNOLOGY.

Andrea Toborelli, Business Development and Licensing Manager at IBSA, was interview by Nutra Horizons. 

As a global pharmaceutical company, IBSA is driven by a distinct vision of care, which starts at the Swiss headquarters and extends globally through continued growth in Europe, Asia, and North America. IBSA’s technologies are aimed at creating more advanced treatment systems to provide healthcare professionals with innovative, effective and reliable therapeutic solutions that improve patients’ quality of life. The product portfolioRead more

24 MAY 2023 From the 19th to the 21st of April 2023, the CPHI Japan fair was held in Tokyo. An ideal business event for international pharmaceutical professionals to grow their business in the rapidly changing Asian market. IBSA took part in the fair, thus having the opportunity to present its innovations in the pharmaceutical field, presenting new products andRead more

IBSA operates in more than 90 countries and 5 continents with 17 subsidiaries in Europe, China and the USA, and employs over 2,000 collaborators distributed among our headquarters, subsidiaries and manufacturing plants. The Group boasts an extensive product portfolio that includes different therapeutic categories, such as prescription drugs, OTC medicines, medical devices and food supplements, and covers 10 therapeutic areas.Read more

IBSA was established in Lugano in 1945 and started developing its special identity in 1985 when it was acquired by the current ownership, which adopted a new strategy focused on the acquisition of technological resources and launched a development programme aimed at consolidating its global expansion and developing company assets. Today IBSA is present in over 90 countries in 5Read more

IBSA will once again be back at CphI Worldwide 2022, Frankfurt, 1-3 November, to present its innovative solutions for the pharmaceutical market, developed in cutting-edge R&D centers and realized in state-of-the art technology production sites.

Andrea Toborelli, Business Development and Licensing Manager at IBSA, was interview by Nutra Horizons.